Camurus Logo

Camurus

Develops and commercializes long-acting medicines for severe and chronic diseases.

CAMX | ST

Overview

Corporate Details

ISIN(s):
SE0007692850 (+2 more)
LEI:
5493003S6Z6VI7WYFQ06
Country:
Sweden
Address:
Ideon Science Park, 223 70 Lund

Description

Camurus is a science-led biopharmaceutical company that develops and commercializes innovative, long-acting medicines for severe and chronic diseases. The company specializes in advanced drug delivery systems designed to improve treatment outcomes, enhance patient quality of life, and provide value to society. Its therapeutic focus areas include opioid dependence, cancer and supportive care, endocrine conditions, rare diseases, and disorders of the central nervous system. Camurus maintains a diversified research and development pipeline to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 07:00
Change in number of shares and votes in Camurus
English 159.5 KB
2025-11-28 07:00
Förändring av antalet aktier och röster i Camurus
Swedish 157.0 KB
2025-11-13 07:00
Valberedning utsedd inför Camurus årsstämma 2026
Swedish 149.2 KB
2025-11-13 07:00
Camurus’ Nomination Committee appointed for the Annual General Meeting 2026
English 151.9 KB
2025-11-10 08:00
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
English 213.9 KB
2025-11-10 08:00
Camurus rapporterar positiva resultat för CAM2056, semaglutid månadsdepå
Swedish 188.3 KB
2025-11-06 07:00 Swedish 1.0 MB
2025-11-06 07:00 English 857.9 KB
2025-09-30 07:00
Förändring av antalet aktier och röster i Camurus
Swedish 134.6 KB
2025-09-30 07:00
Change in number of shares and votes in Camurus
English 136.1 KB
2025-07-17 07:00 Swedish 923.9 KB
2025-07-17 07:00 English 916.2 KB
2025-07-01 11:30
Camurus’ Oczyesa® receives marketing authorization for treatment of acromegaly …
English 184.9 KB
2025-07-01 11:30
Camurus meddelar EU-godkännande av Oczyesa® för behandling av akromegali
Swedish 182.4 KB
2025-06-30 07:00
Förändring av antalet aktier och röster i Camurus
Swedish 130.6 KB

Automate Your Workflow. Get a real-time feed of all Camurus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Camurus

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Camurus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-17 Torsten Malmström Other Sell 10,000 6,806,400.00 SEK
2024-06-17 Jon Uguzne Garay Alonso Other Other 33,750 N/A
2024-05-14 Torsten Malmström Other Sell 1,495 844,675.00 SEK
2024-05-10 Annette Mattsson Other Sell 1,000 550,000.00 SEK
2023-12-15 Annette Mattsson Other Other 1,000 169,500.00 SEK
2023-09-18 Annette Mattsson Other Sell 1,000 294,600.00 SEK
2023-09-06 Maria Lundqvist Other Other 381 N/A
2023-08-23 Maria Lundqvist Other Sell 77 22,610.28 SEK
2023-08-23 Maria Lundqvist Other Sell 58 17,032.86 SEK
2023-08-23 Maria Lundqvist Other Other 77 13,051.50 SEK

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.